Contact
Please use this form to send email to PR contact of this press release:
LyticGen Pharmaceuticals Files Patent for CRISPR-Enhanced Bacteriophage Therapeutic Targeting MRSA
TO:
Milton Arch
LyticGen Pharmaceuticals